ScientiaCME Free CME Courses

  • FREE

    Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

    After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the gene therapy and its anticipated impact on hemophilia B therapy
    • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
    • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

    Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 05, 2019
    • Expiration of CME credit: March 05, 2021
  • FREE

    Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding.

    After completing Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the limitations of annual bleed rate as an epidemiological measure in Hemophilia A
    • Define early prophylaxis in severe hemophilia A and describe its impact on osteochondral damage
    • List evidence-supported benefits of extending clotting factor half lives
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia A, and apply them to patient cases
    • Describe the emerging therapies in the treatment of hemophilia A

     

    Target Audience:

    hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with Hemophilia A.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 04, 2019
    • Expiration of CME credit: March 04, 2021
  • FREE

    Multiple Sclerosis in a Primary Care Setting: Employing Strategies for Appropriate Diagnosis and Improved Patient Outcomes

    Evidence shows that one of the major determinants of how well a patient with MS adheres to therapy is the relationship the patient has with his or her healthcare provider; the degree to which a patient feels support from his or her provider is actually an independent predictor of adherence, according to a survey of patients with self-reported progressive forms of MS.

    After completing Multiple Sclerosis in a Primary Care Setting: Employing Strategies for Appropriate Diagnosis and Improved Patient Outcomes physicians will better be able to:

    • Summarize the pathophysiology, symptomology, and clinical course of MS
    • Formulate strategies to encourage patients to discuss MS’ impact on their activities of daily living in a sensitive manner to identify problems that may be treated
    • Given a patient case, select appropriate treatment options for managing acute exacerbations of MS
    • Given a patient case, select appropriate treatment options for managing chronic symptoms associated with MS
    • Explain effective approaches to promoting patient adherence, managing adverse effects of therapy, and addressing other barriers to care

    Target Audience: Healthcare professionals specializing in: family medicine, geriatrics, internal medicine, primary care, or those who otherwise commonly care for patients with MS in the primary care setting.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 11, 2019
    • Expiration of CME credit: March 11, 2021
  • FREE

    Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment

    The incidence of differentiated thyroid cancer (DTC) is on the rise over the past 10 years and roughly 57,000 new cases were reported in 2017 alone.

    After completing Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment physicians will better be able to: 

    • Recognize factors affecting the diagnosis, staging, and prognosis of patients with DTC.
    • Identify present and emerging pharmacotherapeutic treatments for the management of unresectable DTC and apply them to patient cases using evidence-based medicine
    • Describe how to manage challenges that arise during treatment with approved and investigational medicines for DTC, including adverse effect management, and apply** that knowledge to a patient case
    • Describe the challenges associated with DTC treatment, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, etc.) of the agents used to treat the disease, and apply that information in a patient case

     

    Target Audience: medical oncologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DTC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 15, 2019
    • Expiration of CME credit: March 15, 2021
  • FREE

    Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)

    Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.

    After completing Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018) physicians will better be able to:

    • Summarize the most impactful findings presented at EHA 2018 meeting relating to initial treatment of transplant eligible and ineligible myeloma
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to role of autologous stem cell transplant
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to current role of monoclonal antibodies
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to novel immune therapies

    Target Audience: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 15, 2019
    • Expiration of CME credit: April 15, 2021
  • FREE

    CME: Fabry disease: Updates from recent research findings

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

    After completing this course, physicians will better be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
    • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
    • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
    • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

    Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 6/25/19
    • Expiration of CME credit: 6/25/21
  • FREE

    CME: Glaucoma: Updates from the AAO 2019 Annual Meeting

    Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings at the AAO 2019 meeting relating to glaucoma, including diagnostic testing, therapeutic success, and emerging therapies, and apply that knowledge to patients with different forms of glaucoma
    • Recall the results from the Horizon, LiGHT, and OHTS studies
    • List conditions that can masquerade as normal-tension glaucoma (NTG) and the role of systemic blood pressure in evaluation and management of NTG
    • Summarize the role of the following in glaucoma: hemoglobin video imaging, bimatoprost sustained-release implant, and the microshunt technology

    Target Audience:

    HCPs including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 04/10/2020
    • Expiration of CME credit: 04/10/2021
  • FREE

    CME: Management strategies for complications of chronic kidney disease (CKD): anemia and hyperphosphatemia

    Chronic Kidney Disease (CKD) affects about 15% of the general population in the United States according to data from the CDC’s National Health and Nutrition Examination Survey and causes a number of complications with anemia and hyperphosphatemia common among them. Anemia occurs in about 15% of patients and arises from a result of decreased production of erythropoietin (EPO) which signals bone marrow to produce red blood cells, whereas hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-Mineral Bone Disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on usage of phosphate binders (PBs).

    By the end of the session the participant will be able to:

    • Describe common complications that patients with CKD experience
    • Describe management strategies for anemia and hypherphosphatemia of CKD and their impact
    • Determine appropriateness of therapies for anemia and hypherphosphatemia of CKD, given a patient case
    • Describe effective management strategies for monitoring anemia and hyperphosphatemia in patients with CKD, taking into account dialysis status

    Target Audience:

    The following healthcare professionals (HCPs): nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/5/2020
    • Expiration of CME credit: 3/5/2022
  • FREE

    CME: Hereditary angioedema (HAE): optimizing treatment strategies

    Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease due to C1-inhibitor (C1-INH) deficiency with an estimated frequency of 1 in 50,000 people. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves’ disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality.

    By the end of the session the participant will be able to:

    • Recall the pathophysiology of HAE such that it might inform treatment mechanisms
    • Recognize the risks associated with misdiagnosis of HAE
    • Evaluate a treatment plan for a patient with HAE designed to optimize safety and efficacy, suggesting modifications for improvement
    • Describe present and emerging drug therapies for management of HAE and apply them to patient cases taking into account the patient’s history or anticipated place in therapy

    Target Audience:

    Healthcare professionals who are: allergists, immunologists, and internists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in immunology; and any other HCPs who have an interest in or otherwise clinically encounter patients with HAE.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/23/2020
    • Expiration of CME credit: 3/23/2022
  • FREE

    CME: Advanced prostate cancer: optimizing management strategies

    Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.

    By the end of the session the participant will be able to:

    • Recall the pathophysiology of aPC in a manner that informs treatment mechanisms
    • Describe differences in approach between hormone-sensitive and castration-resistant aPC
    • Identify the treatment modalities currently available for management of aPC and apply them to patient cases using evidence-based medicine
    • Describe emerging treatment options presently available for aPC, their mechanisms of action and safety, and anticipated place in therapy
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/13/2020
    • Expiration of CME credit: 3/13/2021